Pentafluvac “An Indigenous Replication-Incompetent Viral Vaccine for Avian, Swine and Human Influenza”

Introduction

The ongoing global public health burden caused by seasonal influenza and the potential global effect of a severe pandemic create an urgent need for a novel highly effective vaccine that can be manufactured rapidly in a cost-effective way.

Stage of Development

Proof of Concept.

Unique Features of The Product/Technology

The vaccine is live attenuated. Confers protection against influenza caused any strain of the virus. No genetic re-assortment is possible with wild strains.

Market Potential

With the estimated economic growth of vaccine market both at global and national level, development of the proposed vaccine has a positive role to play on market size of influenza vaccine in India as well as worldwide. Unlike other vaccines, the proposed vaccine is an indigenous, rapid in terms of production during outbreaks as the virus back bone for replication incompetent vaccine strain will be ever ready and adapted to cell lines and cheap as it does not require many downstream processing steps.

For further information please contact

Biotechnology Industry Research Assistance Council (BIRAC)

1 st Floor, MTNL Building, 9, CGO Complex,

Lodhi Road, New Delhi- 110003

Phone: + 91-11-24389600

Email- birac.dbt@nic.in